10-K/A: Eyenovia Files Amended 10-K to Include Omitted Information

Eyenovia, Inc. has filed an amendment to its annual report on Form 10-K for the fiscal year ended December 31, 2023, to include previously omitted information regarding directors, executive compensation, and other corporate governance matters.

Summary

• Eyenovia, Inc. filed an amendment to its 2023 annual report on Form 10-K to include information previously omitted from Part III, specifically Items 10 through 14.
• The original 10-K was filed on March 18, 2024, and this amendment, filed on April 26, 2024, addresses the omission by restating these items in their entirety.
• The amendment also updates the number of outstanding shares of common stock to 50,957,869 as of April 16, 2024, and removes the reference to the incorporation by reference of the company's definitive proxy statement.
• The filing includes updated certifications by the principal executive officer and principal financial officer under Section 302 of the Sarbanes-Oxley Act of 2002.
• No financial statements are included in this amendment, and no other changes have been made to the original 2023 10-K, nor does it reflect events occurring after the original filing date.

Sentiment

Score: 6

Explanation: The document is a routine amendment to correct an oversight, which is neither particularly positive nor negative. The company is taking steps to ensure compliance, which is a neutral indicator.

Positives

• The company has taken steps to rectify the omission of required information in its original 2023 10-K filing.
• The updated share count provides current information to investors.
• The inclusion of certifications from the CEO and CFO ensures compliance with regulatory requirements.

Negatives

• The need for an amendment indicates an initial oversight in the filing process.
• The omission of key information in the original filing could have caused confusion or concern among investors.

Risks

• The company's reliance on General Instruction G(3) to Form 10-K may indicate a potential for future omissions if not carefully managed.
• The need for an amendment could raise questions about the company's internal controls and reporting procedures.

Future Outlook

This Form 10-K/A does not reflect events occurring after the date of the filing of the 2023 10-K, nor does it amend, modify or otherwise update any other information in the 2023 10-K.

Management Comments

• Michael Rowe, CEO, certified that the report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report.
• John Gandolfo, CFO, certified that the report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report.

Industry Context

This filing is a standard regulatory requirement for public companies and does not indicate any specific industry trends or competitive pressures.

Comparison to Industry Standards

• The amendment is a standard procedure to correct omissions in SEC filings, which is not uncommon among public companies.
• The company's actions are consistent with the requirements of the Sarbanes-Oxley Act, which mandates certifications from the CEO and CFO.
• The level of detail provided in the amended filing is comparable to other companies of similar size and complexity.

Stakeholder Impact

• Shareholders will receive a more complete picture of the company's governance and executive compensation.
• The company's compliance with SEC regulations will reassure investors and other stakeholders.

Next Steps

• The company will continue to operate as a public company and file future reports as required by the SEC.
• The company will hold its 2024 annual meeting of stockholders.

Key Dates

Keywords

10-K, amendment, directors, executive compensation, corporate governance, financial reporting, Sarbanes-Oxley, SEC filing, Eyenovia